Description
Erlocip Erlotinib 150 mg Tablets is prescribed for non-small cell lung cancer and pancreatic cancer treatment. Acting as an anti-cancer agent, it targets epidermal growth factor receptors (EGFR) present on cancer cell surfaces, hindering their growth. By binding to the chemical messenger EGFR, Erlotinib disrupts cancer signaling pathways mediated by EGFR, effectively restraining the proliferation of cancer cells. This mechanism helps impede the progression of the disease.
